anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To produce a dermatic drug for external use containing the extract of aloe, rapidly in a short time, by crushing and pressing the whole raw leaf of a plant belonging to Aloe genus, Liliaceae family, fermenting the obtained fresh juice and/or the pressed cake with sugar and yeast, and filtering the fermentation liquid. CONSTITUTION:The while raw leaf of a plant belonging to Aloe genus, Liliaceae family, e.g. Aloe arborescens, Cape aloe, Aloe vera, etc. is crushed and pressed. The obtained fresh juice and/or pressed cake are added with (i) a saccharide e.g. monosaccharide such as glucose, disaccharide such as sucrose, or polysaccharide (the amount of the saccharide is preferably 10-15% in terms of alcohol conversion) and (ii) yeast such as brewers' yeast, baker's yeast, etc., and fermented preferably at 25-35 deg.C for 2-4hr. The objective aloe extract liquid useful as an external dermatic drug can be produced economically by filtering the obtained fermentation liquid. Since the extract liquid obtained by the above method contains fermentation metabolites which cannot be attained by conventional extraction process, and is free from characteristic odor, it is useful as an additive for cosmetic, etc.
OBJECTIVE: Inflammation is implicated in the pathophysiology of depression and type 2 diabetes (T2D) and is linked to social determinants of health (SDoH) associated with socioeconomic disadvantage. The objective of this review is to identify and map the range of SDoHs associated with inflammation in depression, T2D, or their co-occurrence among women.
METHODS: PubMed, CINAHL, PsychINFO, and Web of Science were searched March-July 2023 to identify studies where 1) an SDoH was a predictor or independent variable, 2) depression or T2D was a clinical focus, 3) inflammatory markers were collected, and 4) analysis was specific to women. We used the National Institute on Minority Health and Health Disparities research framework to guide searching SDoHs, organize findings, and identify gaps.
RESULTS: Of the 1135 studies retrieved, 46 met criteria. Within the reviewed studies, the most used inflammatory measures were C-reactive protein, interleukin-6, and tumor necrosis factor-α, and the most studied SDoHs were early life stress and socioeconomic status. Individual and interpersonal-level variables comprised the bulk of SDoHs in the included studies, while few to no studies examined built environment (n = 6) or health system level (n = 0) factors. Disadvantageous SDoHs were associated with higher levels of inflammation across the included studies.
CONCLUSION: The scope and intersection of depression and T2D represent a syndemic that contributes to and results from socioeconomic inequities and disproportionately affects women. Simultaneous inclusion of social and inflammatory measures, particularly understudied SDoHs, is needed to clarify potent targets aimed at advancing health and equity.
Subjects will receive a combination of antidepressant medication and physical therapy for 8 months, in addition to their current opioid prescription and weaning guidelines, if applicable. No re-randomization will be done in this treatment group.
Waitlist control. No intervention for first 12 weeks. Participants given the option to participate in the program after 24 weeks.
Based on the Work-Home Resources Model and Conservation of Resources Theory, we develop dual mechanisms by which nice interactions (patients' compliments and coworkers' informational support) predict sleep quality. Specifically, we expect these nice interactions to help individuals conserve their personal energy in the form of less cognitive depletion (a cognitive process) and diminished physical fatigue (a physical process). Further, we propose employees utilise their energy resources to experience better sleep quality. To test the proposed model, we utilised an experience-sampling method by recruiting 223 female nurses working in a regional university hospital in South Korea. Specifically, we measured nice interactions and personal resources at 3 PM on Day t and sleep quality at 5-6 AM on Day t + 1, and we administered the questionnaire for 10 consecutive days. Overall, after removing 79 invalid observations (not completing questionnaire in a timely manner), we had a final total of two-wave 1997 daily observations from 223 nurses. Receiving more compliments from patients and more information from coworkers positively affects nurses' cognitive energy (less cognitive depletion) and physical energy (less physical fatigue), which predicts better sleep quality. Finally, results supported indirect effects of these nice interactions on sleep quality via cognitive and physical processes.
The phenomenon of near-death experience (NDE) is attracting a growing attention among researchers of various fields. In this study, we looked at NDE from a cognitive perspective to find out how NDE events are embodied when people recall and describe them. We examined the descriptions of a group of people talking about what they had experienced in the state of NDE. Based on the gesture-as-simulated-action theory, we assumed that co-speech gestures occurring when people were talking about their experiences were physical realizations of mentally-simulated events. The results showed that the number of iconic and metaphoric gestures occurring with expressions referring to NDE events was significantly larger than those occurred with expressions referring to ordinary events. Based on these results, we suggest that embodied memory for NDE events is stronger than embodied memory for ordinary non-NDE events. NDE events are perceived, recalled, and embodied by strong activation of sensorimotor systems in a state of perceptual and cognitive enhancement, although sensorimotor systems seem to be unresponsive to sensory stimuli during NDE. Finally, based on theories of embodied cognition, we conclude that the enhancement of cognitive functions that takes place in the state of NDE is the result of enhancement in perceptual functions.
PURPOSE:To prepare the titled anti-tumor agent by compounding a 5-fluorouracil derivative with a specific carboxylic acid as a toxicity-reducing agent. CONSTITUTION:The titled agent contains the carboxylic acid derivative of formula (R1 is amino, formyl, etc.; R2 is H or amino; n is 0 or 1) (e.g. ureidopropionic acid) or its salt, and a 5-fluorouracil derivative[e.g. 1-(2-tetrahydrofuryl)- 5-fluorouracil]. 5-Fluorouracil is a nucleic acid antimetabolite having excellent effect especially against adenocarcinoma, and at the same time, remarkable toxicity and side effects. The carboxylic acid derivative of formula and its salt are effective to remarkably reducing the toxicity of the 5-fluorouracil derivative without lowering its anti-tumor activity, and accordingly, increase the tolerance dose of the 5-fluorouracil derivative and imrpve the anti-tumor effect compared with the separate administration. The amount of the carboxylic acid derivative is 1-5pts.wt. per 1pt.wt. of the 5-fluorouracil derivative.
The present invention discloses a Chinese traditional medicine for treating insufficiency of kidney-yang and a preparing method thereof. The Chinese traditional medicine is composed of the following raw materials of the following proportion by weight: 220 to 280 of red ginseng, 390 to 445 of male silkworm moths, 390 to 445 of epimedium (preparation), 390 to 445 of wolfberry fruit, 390 to 445 of mulberry, 220 to 280 of Herba Cistanches (preparation), 130 to 190 of walnut kernels, 100 to 170 of Chinese magnoliavine fruit, 120 to 190 of geckos, 35 to 70 of hippocampus, 35 to 70 of Chinese caterpillar fungus, 220 to 280 of prepared fleeceflower roots and 220 to 280 of milkvetch seeds. The present invention mainly treats old people's body weakness, body weakness after illness, insufficiency of kidneys, impotence, gonacratia, premature ejaculation, soreness and weakness of waists and knees, intolerance of cold limbs, ennui, weakness, dizziness, enechema, continuous dribble of urine, amnesia, severe coma, etc. The present invention has the advantages of short courses of treatment, no side effects, treatment for both manifestation and root causes of diseases, obvious therapeutic effects, etc.; besides, the present invention takes effect quickly; therefore, the effect on prolonging lives is achieved. Simultaneously, the present invention which can also reduce oxygen consumption and increase the resistance of hearts to oxygen deficiency has an obvious effect on nourishing mind.
Pancreatic ductal adenocarcinoma (PDAC) features substantial matrix stiffening and reprogrammed glucose metabolism, particularly the Warburg effect. However, the complex interplay between these traits and their impact on tumor advancement remains inadequately explored. Here, we integrated clinical, cellular, and bioinformatics approaches to explore the connection between matrix stiffness and the Warburg effect in PDAC, identifying CLIC1 as a key mediator. Elevated CLIC1 expression, induced by matrix stiffness through Wnt/β-catenin/TCF4 signaling, signifies poorer prognostic outcomes in PDAC. Functionally, CLIC1 serves as a catalyst for glycolytic metabolism, propelling tumor proliferation. Mechanistically, CLIC1 fortifies HIF1α stability by curbing hydroxylation via reactive oxygen species (ROS). Collectively, PDAC cells elevate CLIC1 levels in a matrix-stiffness-responsive manner, bolstering the Warburg effect to drive tumor growth via ROS/HIF1α signaling. Our insights highlight opportunities for targeted therapies that concurrently address matrix properties and metabolic rewiring, with CLIC1 emerging as a promising intervention point.
BARACLUDE® (entecavir) Tablets and Oral Solution are available in the following strengths and configurations of plastic bottles with child-resistant closures:

BARACLUDE Oral Solution is a ready-to-use product; dilution or mixing with water or any other solvent or liquid product is not recommended. Each bottle of the oral solution is accompanied by a dosing spoon that is calibrated in 0.5 mL increments up to 10 mL.

###  Storage

BARACLUDE Tablets should be stored in a tightly closed container at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Store in the outer carton to protect from light.

BARACLUDE Oral Solution should be stored in the outer carton at 25°C (77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from light. After opening, the oral solution can be used up to the expiration date on the bottle. The bottle and its contents should be discarded after the expiration date.
The needles remained in situ for 30 minutes, during which time the acupuncturist returned to stimulate the needles once to re-elicit the de qi sensation. Participants have 2 sessions per week, with total 5 weeks and 10 sessions. The body points included LI4, LI11, SP6 and ST36. The individual specific points protocol are as follows: GB20, TE5, SP10, GB34, LV3, ba xie, ba fen, Ashi). The acupuncture protocol consists of the body points and some of the individual specific points depending on subjects' condition.
Pharmaceutical prepn. in retard form comprises a core contg. >=1 active substance together with a carrier or excipient. The core is coated with a semipermeable coating of 20-90% water-insoluble film former (I) (e.g. ethyl cellulose) and 10-80% water-soluble polymer (II), e.g. PVP, PEG or methyl cellulose. The release of active substance is independent of pH in the body fluid over the whole period of its activity. The core pH may be reduced by inclusion of acidic material to reduce disintegration time. Dosage regimens are simplified, and initial very high blood levels may be avoided. The core may be in the form of a tablet. The coating pref. has the same permeability over its whole surface. The core may contain an organic food acid to reduce the disintegration time of the core, e.g. citric or tartaric acid is used. The coating may also contain up to 70% water insol. polymer e.g. cellulose acetate.
OBJECTIVE: The aim of this study was to develop a machine learning algorithm using an off-the-shelf digital watch, the Samsung watch (SM-R800), and evaluate its effectiveness for the detection of generalized convulsive seizures (GCS) in persons with epilepsy.
METHODS: This multisite epilepsy monitoring unit (EMU) phase 2 study included 36 adult patients. Each patient wore a Samsung watch that contained accelerometer, gyroscope, and photoplethysmographic sensors. Sixty-eight time and frequency domain features were extracted from the sensor data and were used to train a random forest algorithm. A testing framework was developed that would better reflect the EMU setting, consisting of (1) leave-one-patient-out cross-validation (LOPO CV) on GCS patients, (2) false alarm rate (FAR) testing on nonseizure patients, and (3) "fixed-and-frozen" prospective testing on a prospective patient cohort. Balanced accuracy, precision, sensitivity, and FAR were used to quantify the performance of the algorithm. Seizure onsets and offsets were determined by using video-electroencephalographic (EEG) monitoring. Feature importance was calculated as the mean decrease in Gini impurity during the LOPO CV testing.
RESULTS: LOPO CV results showed balanced accuracy of .93 (95% confidence interval [CI] = .8-.98), precision of .68 (95% CI = .46-.85), sensitivity of .87 (95% CI = .62-.96), and FAR of .21/24 h (interquartile range [IQR] = 0-.90). Testing the algorithm on patients without seizure resulted in an FAR of .28/24 h (IQR = 0-.61). During the "fixed-and-frozen" prospective testing, two patients had three GCS, which were detected by the algorithm, while generating an FAR of .25/24 h (IQR = 0-.89). Feature importance showed that heart rate-based features outperformed accelerometer/gyroscope-based features.
SIGNIFICANCE: Commercially available wearable digital watches that reliably detect GCS, with minimum false alarm rates, may overcome usage adoption and other limitations of custom-built devices. Contingent on the outcomes of a prospective phase 3 study, such devices have the potential to provide non-EEG-based seizure surveillance and forecasting in the clinical setting.
BACKGROUND: In sepsis-associated encephalopathy (SAE), the activation of microglial cells and ensuing neuroinflammation are important in the underlying pathological mechanisms. Increasing evidence suggests that the protein Piezo1 functions as a significant regulator of neuroinflammation. However, the influence of Piezo1 on microglial cells in the context of SAE has not yet been determined. This study aims to investigate the role of Piezo1 in microglial cells in the context of SAE.
METHODS: By inducing cecal ligation and puncture (CLP), a mouse model of SAE was established, while the control group underwent a sham surgery in which the cecum was exposed without ligation and puncture. Piezo1 knockout mice were employed in this study. Morris water maze tests were conducted between Days 14 and 18 postop to assess both the motor activity and cognitive function. A proteomic analysis was conducted to assess the SAE-related pathways, whereas a Mendelian randomization analysis was conducted to identify the pathways associated with cognitive impairment. Dual-label immunofluorescence and flow cytometry were used to assess the secretion of inflammatory factors, microglial status, and oligodendrocyte development. Electron microscopy was used to evaluate axonal myelination. A western blot analysis was conducted to evaluate the influence of Piezo1 on oligodendrocyte ferroptosis.
RESULTS: The results of the bioinformatics analysis have revealed the significant involvement of CCL25 in the onset and progression of SAE-induced cognitive impairment. SAE leads to cognitive dysfunction by activating the microglial cells. The release of CCL25 by the activated microglia initiates the demyelination of oligodendrocytes in the hippocampus, resulting in ferroptosis and the disruption of hippocampal functional connectivity. Of note, the genetic knockout of the Piezo1 gene mitigates these changes. The treatment with siRNA targeting Piezo1 effectively reduces the secretion of inflammatory mediators CCL25 and IL-18 by inhibiting the p38 pathway, thus preventing the ferroptosis of oligodendrocytes through the modulation of the CCL25/GPR78 axis.
CONCLUSION: Piezo1 is involved in the activation of microglia and demyelinating oligodendrocytes in the animal models of SAE, resulting in cognitive impairment. Consequently, targeting Piezo1 suppression can be a promising approach for therapeutic interventions aimed at addressing cognitive dysfunction associated with SAE.
LHWs undergo training over 3 days and recruit 15 participants from their social network. Participants attend a CRC educational session conducted by an LHW over 90 minutes at month 1 and 3. Participants receive phone calls from the LHW at months 2 and 4 reminding them about CRC screening.
The training was a moderate intensity aerobic training on a bicycle ergo-meter(corresponding to 60% to 70% of the maximal heart rate they reach during peak oxygen uptake in the initial exercise test) for 30 to 45 min/day, 3 sessions/week for 12 weeks (36 sessions). In addition to their prescribed medications.
Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Esophageal varices are the most important portosystemic collaterals owing to their rupture results in variceal hemorrhage, which is a devastating event of portal hypertension. Cirrhotic patients surviving a first episode of variceal rupture have a risk of over 60% of suffering from recurrent bleeding within 1 year and mortality from each rebleeding episode is about 20%. Except for patients with a terminal illness, the secondary preventive measures are required to reduce variceal rebleeding to improve patient survival and clinical outcome. Endoscopic and pharmacological therapies are 2 main methods of intervention used to achieve the treatment goals. Endoscopic therapy contains endoscopic injection sclerotherapy (EIS) or endoscopic variceal ligation (EVL), which would obliterate varices by causing thrombosis and fibrosis formation. However, EVL has currently replaced EIS as the endoscopic therapy of choice because it is safer, more effective, and has lower morbidity rate.

Many experts and scholars suggest to repeat EVL every 1-2 weeks until obliteration of esophageal varices to prevent variceal rebleeding, whereas, there are insufficient data to support the concept that EVL at intervals of 1-2 week is appropriate. Our previous studies demonstrated that repeating EVL every 3-4 weeks could achieve an appreciable low incidence of variceal rebleeding and mortality. In our own opinion, many shallow post-EVL ulcers may hamper the performance of variceal ligation if EVL is performed at intervals of 1-2 weeks. A randomized controlled trial from Japan showed that EVL performed at a bimonthly interval obtained a higher variceal obliteration rate, lower variceal recurrence rate and fewer additional treatments. Bimonthly EVL in the secondary prophylaxis of variceal hemorrhage may be theoretically improper because post-EVL variceal rebleeding could only be significantly reduced in whom variceal obliteration was achieved within a short treatment course. The other retrospective investigation from the United States demonstrated the principal technical aspects of EVL in the prevention of variceal rebleeding, suggesting the benefit of intersession intervals \> 3 weeks compared with intervals \< 3 weeks.

This randomized controlled study was undertaken to compare the effectiveness and safety of EVL with two different intersession intervals (bimonthly vs. biweekly). In addition, the risk factors that were associated with variceal rebleeding and mortality were analyzed.
The Proprioceptive Neuromuscular Facilitation group (PNFG) intervention consisted of applying PNF concept exercises and techniques related to facilitating sitting and walking, carried out by a therapist with basic IPNFA® (International Proprioceptive Neuromuscular Facilitation Association) instruction. The PNF intervention was divided into two stages: Stage 1: which consisted of facilitating stability and controlled mobility of the initial position and phases 1, 2, 3, of the sit-up. At the initial position, we applied PNF stabilizing reversals technique for 2 minutes, to stimulate stability in the upright sitting position. In phase 1, we applied PNF to stimulate controlled mobility of the anterior inclination of the erect trunk. In Phase 2, to improve the concentric and eccentric control of lower limb extensor muscles and, in Phase 3 to improve the stability in an upright position again. Stage 2: consists of facilitating activities related to gait.
The invention relates to compositions and methods (with regard to animals and humans) for utilizing an extract and/or one or more natural spiro triterpenoids and derivatives thereof alone or as a supplement. Certain materials utilized are from the blazeispirol family, obtainable from  Agaricus  species. Treatments include the prophylactic and/or therapeutic treatment of a disease, disorder or condition that responds to the modulation of Liver X receptor, as well as corresponding methods of treatment, the manufacture of a pharmaceutical and nutraceutical formulation for said treatment. The invention also relates to the use of the extract and compound(s) in the treatment or in the preparation of a medicament (e.g. a nutraceutical) for the prophylactic and/or therapeutic treatments, as well as their preparation. It also relates to pharmaceutical or nutraceutical formulations described herein which are useful in prophylactic and therapeutic treatments. They can also be used for non-therapeutic, e.g. cosmetic, purposes.
PURPOSE:To protect the privacy of patients by providing a function which classifies patient information according to privacy and requires the consent of patients for referring to, opening, and transferring the information having higher classes of privacy. CONSTITUTION:When a patient comes to a hospital for the first time, a consultation card is prepared at by means of an MWS for new patients. On this consultation card, fingerprint information is also stored in addition to ordinary patient information. The past history of the patient obtained through consultation is registered on the card. When the past history is registered, the past history is classified to Class 2 privacy. The other information is also registered after the information is classified according to privacy. When the information of the patient is referred to at the MWS, the operator first makes operator's own registration card read by the MWS 3. On the registration card, such identifying information as password, fingerprint, etc., and the privacy handling class of the card holder are registered in advance. Then the operator inputs operator's password, fingerprint, etc., as operator's own identification information for identification.
This represents 6 individual script-based sessions lasting 1h, distributed over 8 weeks, administered by a certified expert in therapeutic hypnosis. A set of standardized recordings are provided to use at home for self-hypnosis. Suggestions address deep relaxation, sensory substitution or transformation, pain intensity reduction, decreased pain unpleasantness and intensity, sense of control. A brief example of such suggestions: "in this deeply relaxed state, you can imagine that your feet are covered in anesthetic... a deep layer of a powerful anesthetic medication, creating protective, soothing socks with which you can walk again...".